Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00504205 · ClinicalTrials.gov registry record · NA
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
A NA study, sponsored by Astex Pharmaceuticals.
- Terminated
- Registry status
- NA
- Development phase
- 30
- Enrollment target
NCT00504205: Clinical Trial NA study, sponsored by Astex Pharmaceuticals.
NCT00504205 is a NA study that was terminated before completion, run by Astex Pharmaceuticals. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00504205, a NA study, was terminated before completion, sponsored by Astex Pharmaceuticals.
- TERMINATED
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
Study Summary
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or non-Hodgkin's lymphoma.
Interventions
- OTHER laboratory biomarker analysis
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- DRUG multitargeted receptor tyrosine kinase inhibitor MP470
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-05 |
| Est. Completion | 2010-03 |
| Phase | NA |
Why NCT00504205 stopped before completion
NCT00504205 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00504205 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00504205 about?
NCT00504205 is a clinical study titled "MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma". RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable or metastatic refractory solid tumor, Hodgkin's lymphoma, or non-Hodgk...
What is the current status of trial NCT00504205?
This trial is currently terminated. It is a NA study. The enrollment target is 30 participants. The study started on 2007-05. Estimated completion is 2010-03.
What interventions are being tested in trial NCT00504205?
The interventions under investigation include: laboratory biomarker analysis (OTHER), pharmacological study (OTHER), positron emission tomography (PROCEDURE), multitargeted receptor tyrosine kinase inhibitor MP470 (DRUG).
Who is sponsoring clinical trial NCT00504205?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00504205's enrollment target sits among peer trials
30 1593rd of 2000 higher than 299 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia